Skip to main content
DOCS logo

DOCS · Doximity, Inc. · Documents

Track DOCS — free
Market Cap
$5.95B
Shares
178.41M
Volume · Nov 16 606.74K Avg daily vol (3M) 2.84M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2026 Revenue $644.86M up 13.1% 10-K filed May 19, 2026 Quarterly report FY2027 Q2 Revenue $174.54M up 3.6% 10-Q filed Nov 5, 2026 Latest results Revenue rises 4% as net income falls 8-K filed Nov 5, 2026 Earnings call Q2 2027 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
Revenue outlook raised as AI Search gains traction

Doximity reported Q2 revenue of $174.5 million, up 4% year-on-year, raised FY27 revenue guidance to $678 to $683 million, and said AI Search became an eight-figure bookings product, with 16 of the top 20 pharma companies purchasing programs.

4 source passages
Q2 revenue of $174.5 million outperformed our guidance with 4% year-over-year growth. For FY27, we've raised our revenue guidance range to $678 to $683 million, also representing 6% growth at the midpoint. AI Search is now an eight-figure bookings product To date, we've seen early broad-based adoption with 16 of the top 20 pharma companies having purchased programs, and three more are in our pipeline. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2027 Q2, ended Sep 30
Revenue grew 4% while gross margin fell 5 percentage points

Doximity reported revenue of $174.5 million for the three months ended September 30, 2026, up 4% from $168.5 million. Net income fell to $34.7 million from $62.1 million, while gross margin decreased 5 percentage points due to increased costs supporting AI initiatives.

Revenue $174.54M ▲ 3.6% Net income $34.73M ▼ 44.0% Diluted EPS $0.18 ▼ 41.9%
Read from the MD&A section
4 source passages
This guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians and their colleagues. For the three months ended September 30, 2026 and 2025, we recognized revenue of $174.5 million and $168.5 million, respectively, representing a year-over-year growth rate of 4%. For the three months ended September 30, 2026 and 2025, our net income was $34.7 million and $62.1 million and our adjusted EBITDA was $88.9 million and $100.8 million, respectively. Gross margin for the three and six months ended September 30, 2026 decreased 5 percentage points as compared to the same period in 2025, primarily due to the increased cost of revenue incurred to support our AI initiatives. Open the document at this passage
Nov 5
Current report 8-K
Revenue rises 4% as net income falls

Doximity reported fiscal 2027 second-quarter revenue of $174.5 million, up 4% year-over-year, while net income fell to $34.7 million. It expects fiscal 2027 revenue of $678 million to $683 million.

Financial results
5 source passages
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 second quarter ended September 30, 2026. Revenue: Revenue of $174.5 million, versus $168.5 million, an increase of 4% year-over-year. Net income and non-GAAP net income: Net income of $34.7 million, versus $62.1 million, representing a margin of 19.9%, versus 36.8%. Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows: Revenue between $678 million and $683 million. Open the document at this passage
Aug 6
Quarterly report 10-Q FY2027 Q1, ended Jun 30
Quarterly report for FY2027 Q1 AI summary on its way
Revenue $156.62M ▲ 7.3% Net income $24.32M ▼ 54.4% Diluted EPS $0.13 ▼ 51.9%
Jul 15
Proxy statement DEF 14A Meeting Aug 27, 2026
Proxy statement AI summary on its way
May 19
Annual report 10-K FY2026, ended Mar 31
Annual report for FY2026 AI summary on its way
Revenue $644.86M ▲ 13.1% Net income $196.05M ▼ 12.2% Diluted EPS $0.98 ▼ 11.7%
Feb 5
Quarterly report 10-Q FY2026 Q3, ended Dec 31
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $185.05M ▲ 9.8% Net income $61.56M ▼ 18.1% Diluted EPS $0.31 ▼ 16.2%
2025
Nov 6
Quarterly report 10-Q FY2026 Q2, ended Sep 30
Quarterly report for FY2026 Q2
Revenue $168.53M ▲ 23.2% Net income $62.06M ▲ 40.6% Diluted EPS $0.31 ▲ 40.9%
Aug 7
Quarterly report 10-Q FY2026 Q1, ended Jun 30
Quarterly report for FY2026 Q1
Revenue $145.91M ▲ 15.2% Net income $53.32M ▲ 28.9% Diluted EPS $0.27 ▲ 28.6%
May 20
Annual report 10-K FY2025, ended Mar 31
Annual report for FY2025
Revenue $570.4M ▲ 20.0% Net income $223.19M ▲ 51.2% Diluted EPS $1.11 ▲ 54.2%
Feb 6
Quarterly report 10-Q FY2025 Q3, ended Dec 31
Quarterly report for FY2025 Q3
Revenue $168.6M ▲ 24.6% Net income $75.2M ▲ 56.8% Diluted EPS $0.37 ▲ 54.2%
2024
Nov 7
Quarterly report 10-Q FY2025 Q2, ended Sep 30
Quarterly report for FY2025 Q2
Revenue $136.83M ▲ 20.4% Net income $44.15M ▲ 44.3% Diluted EPS $0.22 ▲ 46.7%
Aug 8
Quarterly report 10-Q FY2025 Q1, ended Jun 30
Quarterly report for FY2025 Q1
Revenue $126.68M ▲ 16.8% Net income $41.38M ▲ 45.7% Diluted EPS $0.21 ▲ 61.5%
May 23
Annual report 10-K FY2024, ended Mar 31
Annual report for FY2024
Revenue $475.42M ▲ 13.5% Net income $147.58M ▲ 30.8% Diluted EPS $0.72 ▲ 35.8%
Showing 1–50 of 90 documents
Key facts CIK 1516513 CUSIP 26622P107 13F (30d) 340 filings 296 filers Visit website Investor relations